Open Accessibility Menu

Clinical Trial Information

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis

Study Details

The goal of this study is to evaluate the efficacy and safety of baricitinib 1-mg daily and 2-mg daily in comparison to placebo in adult patients with moderate to severe atopic dermatitis. The study is divided into 3 periods: a 5-week Screening Period, a 104-week Double-Blinded Treatment Period, and a 4-week Post-Treatment Follow-Up Period.

Primary Sponsor:

Eli Lilly and Company

Prinicipal Investigator:

Dr. Maria Sotomayor, MD/Dermatology

Contact Phone:

(202) 677-6160
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis mrengifopardo@mfa.gwu.edu

Interested in More Information

  • Please enter your first name.
  • Please enter your last name.
  • This isn't a valid email address.
    Please enter your email address.
  • This isn't a valid phone number.
    Please enter your phone number.
    You entered an invalid number.
  • Please enter your address.
  • Please enter your city.
  • Please enter your state.
  • Please enter your zip code.
  • (All Uppercase. No Spaces)